MARKET

AGLE

AGLE

Aeglea Biotherap
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.500
-0.010
-0.66%
After Hours: 1.500 0 0.00% 16:00 05/20 EDT
OPEN
1.530
PREV CLOSE
1.510
HIGH
1.560
LOW
1.450
VOLUME
147.22K
TURNOVER
0
52 WEEK HIGH
8.50
52 WEEK LOW
1.290
MARKET CAP
91.76M
P/E (TTM)
-1.0283
1D
5D
1M
3M
1Y
5Y
BRIEF-Aeglea Bio Entered Into Sales Agreement With Jonestrading
reuters.com · 2d ago
Aeglea BioTherapeutics Says Entered Into Sales Agreement With JonesTrading, Dated May 20, 2022, Relating To Sale Of Up To $60M Shares Of Co's Common Stock
On May 20, 2022, Aeglea BioTherapeutics, Inc. (the “Company”) entered into a Capital on DemandTM Sales Agreement (the “Offering Agreement”) with JonesTrading Institutional Services LLC,
Benzinga · 2d ago
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
Zacks · 2d ago
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
Zacks · 4d ago
Horizon (HZNP) Begins Enrollment in Alopecia Areata Study
Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.
Zacks · 4d ago
Seagen's (SGEN) Stock Up on CEO's Resignation Announcement
Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.
Zacks · 5d ago
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.
Zacks · 05/13 14:30
Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs
Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.
Zacks · 05/11 13:47
More
No Data
Learn about the latest financial forecast of AGLE. Analyze the recent business situations of Aeglea Biotherap through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
87.50%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AGLE stock price target is 8.86 with a high estimate of 17.00 and a low estimate of 4.000.
High17.00
Average8.86
Low4.000
Current 1.500
EPS
Actual
Estimate
-0.30-0.22-0.15-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 119
Institutional Holdings: 44.05M
% Owned: 72.01%
Shares Outstanding: 61.17M
TypeInstitutionsShares
Increased
26
3.38M
New
18
763.47K
Decreased
22
4.64M
Sold Out
9
193.35K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
Russell Cox
President/Chief Executive Officer/Director
Anthony Quinn
Chief Financial Officer
Jonathan Alspaugh
Chief Operating Officer
Leslie Sloan
Other
Michael Hanley
Independent Director
V. Bryan Lawlis
Independent Director
Alison Lawton
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
Sandesh Mahatme
Independent Director
Armen Shanafelt
Independent Director
Hunter Smith
Independent Director
Marcio Souza
No Data
No Data
About AGLE
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGLE stock methods without spending real money on the virtual paper trading platform.